Novo Nordisk - 44 Year Stock Price History | NVO

Historical daily share price chart and data for Novo Nordisk since 1981 adjusted for splits and dividends. The latest closing stock price for Novo Nordisk as of April 22, 2025 is 59.91.
  • The all-time high Novo Nordisk stock closing price was 144.04 on June 25, 2024.
  • The Novo Nordisk 52-week high stock price is 148.15, which is 147.3% above the current share price.
  • The Novo Nordisk 52-week low stock price is 57.00, which is 4.9% below the current share price.
  • The average Novo Nordisk stock price for the last 52 weeks is 110.77.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novo Nordisk Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2025 77.7330 86.1321 89.5077 58.0800 59.9100 -29.23%
2024 120.8440 99.3965 144.0370 83.6520 84.6558 -15.93%
2023 82.3595 65.8203 102.6480 63.6000 100.7010 54.83%
2022 52.3586 51.5168 65.0418 44.0869 65.0418 22.63%
2021 41.7712 33.1707 55.4425 31.1414 53.0369 63.51%
2020 29.8798 26.5206 34.2713 22.4762 32.4370 23.32%
2019 23.0528 20.7606 26.4752 20.5698 26.3025 28.67%
2018 21.2174 23.4741 25.1991 18.4312 20.4412 -12.13%
2017 18.3943 15.1048 23.2877 13.8685 23.2617 54.26%
2016 20.2048 23.4517 23.9518 13.2756 15.0796 -36.56%
2015 21.8944 17.1218 24.6509 16.8841 23.7710 39.39%
2014 17.8176 14.5259 19.7572 14.5259 17.0533 16.67%
2013 13.4621 12.8791 15.0857 11.9104 14.6169 15.35%
2012 11.3934 8.9234 13.2075 8.8090 12.6718 44.10%
2011 8.7945 8.3541 10.0274 7.2160 8.7937 3.97%
2010 6.4467 4.8471 8.4578 4.7518 8.4578 79.38%
2009 4.1400 3.8121 5.1195 3.0992 4.7149 27.12%
2008 4.3326 4.5408 5.2707 3.1770 3.7089 -19.65%
2007 3.7770 2.9265 4.8433 2.8841 4.6162 57.42%
2006 2.3510 1.9633 2.9577 1.8940 2.9325 51.04%
2005 1.8306 1.8010 2.0644 1.6732 1.9416 5.30%
2004 1.6687 1.3796 1.8693 1.3110 1.8439 34.57%
2003 1.1636 0.9682 1.3702 0.8349 1.3702 43.96%
2002 1.0416 1.3070 1.3371 0.7347 0.9518 -27.18%
2001 1.3114 1.1502 1.5068 1.1308 1.3070 14.19%
2000 1.1055 0.8581 1.4496 0.7902 1.1446 38.81%
1999 0.7386 0.8815 0.8815 0.6095 0.8246 -1.70%
1998 0.8836 0.8954 1.0676 0.6828 0.8389 -7.45%
1997 0.6734 0.5624 0.9080 0.5499 0.9064 55.13%
1996 0.4613 0.4322 0.5921 0.3936 0.5843 38.17%
1995 0.3425 0.2865 0.4229 0.2773 0.4229 45.33%
1994 0.3049 0.3002 0.3370 0.2696 0.2910 -3.06%
1993 0.2701 0.2659 0.3002 0.2365 0.3002 12.27%
1992 0.2652 0.2717 0.2900 0.2395 0.2674 -0.19%
1991 0.2098 0.1847 0.2769 0.1691 0.2679 44.81%
1990 0.1525 0.1456 0.1902 0.1309 0.1850 26.19%
1989 0.1288 0.1121 0.1521 0.1121 0.1466 30.78%
1988 0.0937 0.0657 0.1208 0.0657 0.1121 84.68%
1987 0.0950 0.0930 0.1177 0.0572 0.0607 -34.31%
1986 0.0863 0.0803 0.0966 0.0737 0.0924 13.51%
1985 0.0776 0.0648 0.0962 0.0631 0.0814 25.62%
1984 0.1138 0.1533 0.1655 0.0587 0.0648 -57.26%
1983 0.1581 0.1139 0.1970 0.1139 0.1516 28.58%
1982 0.1117 0.1055 0.1377 0.0938 0.1179 11.02%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $260.636B $42.122B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $796.425B 64.61
Johnson & Johnson (JNJ) United States $379.479B 15.67
AbbVie (ABBV) United States $306.016B 17.09
Roche Holding AG (RHHBY) Switzerland $248.102B 0.00
Novartis AG (NVS) Switzerland $234.183B 14.19
Merck (MRK) United States $196.697B 10.21
Sanofi (SNY) France $128.587B 12.24
Pfizer (PFE) United States $125.566B 7.12
Bayer (BAYRY) Germany $23.657B 4.39
Innoviva (INVA) United States $1.145B 10.56